No abstract available
Keywords:
advanced melanoma; clearance; exposure-response; nivolumab; overall survival; population pharmacokinetics.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antineoplastic Agents, Immunological / adverse effects
-
Antineoplastic Agents, Immunological / blood
-
Antineoplastic Agents, Immunological / therapeutic use
-
Bayes Theorem
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase III as Topic
-
Disease-Free Survival
-
Female
-
Humans
-
Male
-
Melanoma / blood*
-
Melanoma / drug therapy*
-
Melanoma / mortality
-
Middle Aged
-
Nivolumab / adverse effects
-
Nivolumab / blood*
-
Nivolumab / therapeutic use*
-
Randomized Controlled Trials as Topic
-
Survival Rate
Substances
-
Antineoplastic Agents, Immunological
-
Nivolumab